Camurus recognized in Fortune’s Top 25 “Leading the charge: Spotlighting the 25 companies smashing the glass ceiling”

Camurus has been named among the top 25 companies in Fortune’s new editorial list titled “Leading the charge: Spotlighting the 25 companies smashing the glass ceiling”, which recognizes innovative, growing companies with a strong focus on diversity and gender parity in leadership positions.

Camurus has over the last couple of years achieved significant progress and sustainable profitability. The inclusion is a recognition of the company’s advancement, and the strong employee engagement and steadfast drive for the commitment of improving the lives of patients with severe and chronic diseases.

Fortune is a global business magazine, known for its rankings such as Fortune 500.

For more information about the list: https://fortune.com/europe/2024/07/24/leading-the-charge-these-25-female-heavy-c-suites-highlight-the-dearth-of-women-in-europes-boardroom/

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.